Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris

Inclusion Criteria: * Participants with a clinical diagnosis of moderate to severe interdigital tinea pedis, as defined by a Physician's Global Assessment (PGA) score of 2 or 3 on both feet, and moderate to severe tinea cruris, as defined by a PGA score of 2 or 3 * Participants with a mycological diagnosis of tinea pedis and tinea cruris confirmed by the detection of fungal hyphae on a microscopic potassium hydroxide (KOH) wet mount * Participants must be in good general health and free of any disease that might interfere with study evaluations * Participants with the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study Exclusion Criteria: * Female participants who are pregnant and/or nursing or planning a pregnancy during the course of the trial * Participants who are immunocompromised * Participants who have a recent history of or currently known drug or alcohol abuse * Participants with a history of intolerance or hypersensitivity to imidazole compounds, proton pump inhibitors, or the inactive components of luliconazole cream 1% or omeprazole * Participants with a life-threatening condition within the last 6 months * Participants with uncontrolled diabetes mellitus * Participants who are unable to communicate or cooperate with the Investigator * Participants using medications for treatment of tinea pedis and/or tinea cruris (see Investigator for length of time prior to study start) * Participants receiving concomitant drugs that are known to inhibit and/or induce CYP2C19 and/or CYP3A4, or that interact with omeprazole * Because of the potential for drug interaction with luliconazole, administration with medications that are known to be substrates of CYP3A4, CYP2B6, CYP2C8, and CYP2C19 should be carefully monitored